Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
The overall response rate to afatinib is comparable to a
2021-09-15
The 13% overall response rate to afatinib is comparable to a 19% response rate reported by Peters et al. [20] in a separate retrospective series investigating the use of afatinib in more heavily pretreated patients with HER2-mutant lung adenocarcinomas. Our 13% response rate is also comparable to an
-
Immunohistochemical evaluation of gastric cancer tumor
2021-09-15
Immunohistochemical evaluation of gastric cancer tumor samples revealed that 57.8% (59/101) were positive for GLI1, and 71.3% (72/101) stained positive for SHH [27]. Overexpression of SHH and GLI1 protein were significantly associated with larger tumor size, tumor aggressiveness, and less differenti
-
potassium hydrochloride mg Table shows the distribution of a
2021-09-15
Table 3 shows the distribution of all studied groups regarding mutation of GSTP1 gene polymorphism in each group. From 15 COPD smoker patients in group (A), 12 (80%) had heterozygous mutation, from 15 COPD non-smoker patients in group (B), 5 (33.3%) had heterozygous mutation, from 10 control subject
-
Pharmacologic approaches of inhibiting GSNOR activity have r
2021-09-15
Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications
-
We also examined possible involvement of the
2021-09-15
We also examined possible involvement of the NF-κB signaling pathway in GSK-3 inhibitor-induced suppression of PGE2 production, whereas GSK-3 inhibitors did not have a significant effect on IκB phosphorylation/degradation or NF-κB nuclear translocation. These results are consistent with a previous p
-
The ER is responsible for calcium
2021-09-15
The ER is responsible for calcium storage, lipid and protein biosynthesis, and the folding, assembly, and maturation of proteins [23], and ER stress is one of the main causes in T2DM, which leads to β-cell apoptosis and dysfunction [[5], [6], [7]]. In this study, TG was used as an ER stress inducer.
-
Initially we carried out gap FRAP experiments using the
2021-09-14
Initially, we carried out gap-FRAP experiments using the two-photon configuration of the confocal microscope. A SR101-positive astrocyte was targeted and a 5 × 5 μm square area was exposed to a laser illumination (5 flashes of 5 s each during 25 s). This procedure resulted in a bleaching of this ast
-
Hypertriglyceridemia is associated with an overproduction an
2021-09-14
Hypertriglyceridemia is associated with an overproduction and secretion of triglyceride-rich lipoproteins (TRLs), due to increased liver lipid substrate availability (Adiels et al., 2005, Choi and Ginsberg, 2011), and/or reduced catabolism of TRLs and their remnants, due to reduced lipoprotein lipas
-
The glycolytic activator phosphofructo kinase fructose bisph
2021-09-14
The glycolytic activator 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase 3 (PFKFB3) is well-known as a downstream substrate of hypoxia-inducible factor 1α (HIF-1α) signaling pathway [5,6]. Tumor hypoxia has long been associated with increased malignancy, poor prognosis and drug resistance. HIF-
-
Apigenin trihydroxyflavone a natural plant flavone is
2021-09-14
Apigenin (4′, 5, 7-trihydroxyflavone), a natural plant flavone, is a bioactive compound present in a variety of fruits, vegetables, and medicinal plants, and its various beneficial biological activities have been reviewed (Zhou et al., 2017), including HIF-1α inhibition-mediated anti-tumor. Recently
-
Human epidermal growth factor receptor HER
2021-09-14
Human epidermal growth factor receptor 2 (HER2/neu, also known as CerbB-2, or ERBB-2) is a proto-oncogene located on chromosome 17q21, which encodes a transmembrane protein with tyrosine kinase activity, and belongs to the HER receptor family (EGFR, named also HER1, HER3, and HER4) [6]. HER2 is invo
-
The synthesis of target compound RS C is illustrated as
2021-09-14
The synthesis of target compound (RS)-C02 is illustrated as Scheme 2. Compound (RS)-3 was synthesized as reported procedures [40] and then reacted with ethyl piperidine-4-carboxylate to yield (RS)-C01, which subsequently was converted to target molecule (RS)-C02 by performing a nucleophilic substitu
-
simvastatin zocor HCV NS A inhibits induction of the type I
2021-09-14
HCV NS3/4A inhibits induction of the type I interferon response by cleaving MAVS from the mitochondrial surface (Li et al., 2005b). MAVS is cleaved at cysteine 508, and simvastatin zocor of cysteine 508 to arginine (C508R) abrogates cleavage (Li et al., 2005b). GBV-B and the related canine hepatiti
-
After brain injury adenosine levels rapidly increase in
2021-09-14
After brain injury, adenosine levels rapidly increase in the brain [9,10]. As shown in our previous studies, the increased adenosine concentration acts on adenosine A2A receptors (A2ARs), increasing post-traumatic glutamate levels in the brain and exacerbating the severity of injuries [11,12]. Accor
-
br Acknowledgments The breast cancer laboratory
2021-09-13
Acknowledgments The breast cancer laboratory is supported by the Australian National Health and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852, no. 1086727; NHMRC IRIISS; the Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium and Op
13929 records 549/929 page Previous Next First page 上5页 546547548549550 下5页 Last page